JAK(i) of All Trades: Navigating Myelofibrosis Treatment and Safety in Community Oncology Practice

4/30 Myelofibrosis at 10:15am ET: https://event.arraylive.com/ap...

This satellite symposium will be broadcast live from the 2025 Community Oncology Conference in Lake Buena Vista, Florida. If you would like to attend in-person, please click here to register.

Program Description

Myelofibrosis is a rare myeloproliferative neoplasm that presents with symptoms including bone marrow fibrosis, splenomegaly, anemia, thrombocytopenia, and inflammation. The JAK/STAT pathway has an established role in myelofibrosis pathogenesis, and research has led to the development of JAK inhibitors (JAKi) which provide significant benefits to patients, including spleen reduction and symptom relief. However, choosing the most appropriate agent is challenging due to evolving evidence and medication-specific adverse effects. Oncology pharmacists within community oncology practices must be prepared to aid in adverse effect management as well as guiding the transition from one JAKi to another. This session will emphasize the role of emerging JAKi therapies within myelofibrosis, highlighting recent updates in treatment guidelines, considerations for individualized treatment decisions, and safe transitions of therapy to reduce ruxolitinib discontinuation syndrome. Expert faculty will also share clinical pearls for improving adherence to oral therapies in myelofibrosis management.

Target audience: Oncology pharmacists and specialty pharmacists

Type of activity: Application
Release date: April 30, 2025
Expiration date: June 30, 2025

Time to complete activity: 0.75 hour

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the role of JAK inhibitors in frontline and subsequent treatment of myelofibrosis based on individual patient characteristics and disease progression
• Analyze clinical approaches to ensure smooth transitions between JAK inhibitor therapies, minimizing the risk of ruxolitinib discontinuation syndrome in patients with myelofibrosis
• Differentiate the distinct adverse effect profiles and management strategies for JAK inhibitors in myelofibrosis, ensuring optimal patient adherence and improved outcomes

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-25-060-L01-P. The activity is available for CE credit through June 30, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Shawn P. Griffin, PharmD, BCOP

Syed Zia Khan, PharmD, BCSCP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms